3 Promising US Penny Stocks With Over $9M Market Cap

As the U.S. stock market looks to recover from a recent losing streak, with major indices like the Dow Jones and Nasdaq showing signs of strength, investors are exploring diverse opportunities across various sectors. Penny stocks, though sometimes overlooked due to their historical connotations, remain a viable investment option when backed by strong financials. In this article, we explore three penny stocks that exhibit financial robustness and potential for growth, offering investors a chance to uncover hidden value in promising companies.

Click here to see the full list of 726 stocks from our US Penny Stocks screener.

Let’s dive into some prime choices out of the screener.

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: 23andMe Holding Co. is a consumer genetics testing company operating in the United States, the United Kingdom, Canada, and internationally, with a market cap of $83.97 million.

Operations: The company generates revenue of $193.26 million from its Consumer & Research Services segment.

Market Cap: $83.97M

23andMe Holding Co., with a market cap of US$83.97 million, faces significant challenges typical of penny stocks, including high volatility and recent shareholder dilution. The company is unprofitable, with earnings declining by 32.1% annually over the past five years. Despite having no debt and short-term assets exceeding liabilities, its cash runway is under a year due to negative free cash flow. Recent strategic shifts include discontinuing therapeutics development and exploring alternatives for these assets while forming new alliances like that with Mirador Therapeutics to leverage its extensive genetic database for precision medicine advancements.

• Unlock comprehensive insights into our analysis of 23andMe Holding stock in this financial health report.

• Gain insights into 23andMe Holding’s historical outcomes by reviewing our past performance report.

Simply Wall St Financial Health Rating: ★★★★☆☆